Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight
Frontiers in Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Март 26, 2025
Glaucoma,
a
leading
cause
of
irreversible
blindness,
represents
significant
challenge
in
ophthalmology.
This
review
examines
recent
advancements
glaucoma
treatment,
focusing
on
innovative
medications
and
creative
strategies.
While
new
agents
offer
promising
methods
for
lowering
intraocular
pressure
(IOP),
they
also
pose
challenges
related
to
efficacy
side
effects.
Alongside
IOP
reduction,
emerging
neuroprotective
approaches
are
being
explored
safeguard
retinal
ganglion
cells
(RGCs)
from
glaucoma-induced
damage.
The
evaluates
the
potential
novel
drug
delivery
systems,
such
as
biodegradable
implants
nanoparticles,
enhance
treatment
effectiveness
patient
adherence.
Additionally,
it
highlights
role
personalized
medicine
identifying
biomarkers
customizing
therapies
based
individual
genetic
environmental
factors.
Язык: Английский
Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways
World Journal of Cardiology,
Год журнала:
2024,
Номер
16(11), С. 632 - 643
Опубликована: Окт. 30, 2024
As
a
non-communicable
disease,
cardiovascular
disorders
have
become
the
leading
cause
of
death
for
men
and
women.
Of
additional
concern
is
that
disease
linked
to
chronic
comorbidity
include
nonalcoholic
fatty
liver
(NAFLD).
NAFLD,
also
termed
metabolic-dysfunction-associated
steatotic
greatest
throughout
world,
increasing
in
prevalence
concurrently
with
diabetes
mellitus
(DM),
can
progress
steatohepatitis
leads
cirrhosis
fibrosis.
Individuals
metabolic
disorders,
such
as
DM,
are
more
than
two
times
likely
experience
cardiac
stroke,
includes
NAFLD
when
compared
individuals
without
disorders.
Interestingly,
share
common
underlying
cellular
mechanism
pathology,
namely
silent
mating
type
information
regulation
2
homolog
1
(SIRT1;
Язык: Английский